Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis

Hassan Alaa Hammed al-Shammaa, Yan Li, Yutaka Yonemura

Hassan Alaa Hammed al-Shammaa, Yan Li, Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China
Yutaka Yonemura, Peritoneal Carcinomatosis Program, Shizuoka Cancer Center, Mishima, Japan

Supported by New-Century Excellent Talents Supporting Program of the Ministry of Education of China NCET-04-0669, Foundation for the Author of National Excellent Doctoral Dissertation of China; FANEDD-200464, Young Talents Supporting Program of Hubei Province 301161202, and National Natural Science Foundation of China No. 20675058

Correspondence to: Yan Li, MD, PhD, Department of Oncology, Zhongnan Hospital of Wuhan University, Cancer Center of Wuhan University, and Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. liyanasd2@163.com
Telephone: +86-27-62337478 Fax: +86-27-67812892
Received: August 20, 2007 Revised: December 8, 2007

Abstract

This article is to offer a concise review on the use of cytoreductive surgery (CRS) plus intraperitoneal hyperthermic chemotherapy (IPHC) for the treatment of peritoneal carcinomatosis (PC). Traditionally, PC was treated with systemic chemotherapy alone with very poor response and a median survival of less than 6 mo. With the establishment of several phase II studies, a new trend has been developed toward the use of CRS plus IPHC as a standard method for treating selected patients with PC, in whom sufficient cytoreduction could be achieved. In spite of the need for more high quality phase III studies, there is now a consensus among many surgical oncology experts throughout the world about the use of this new treatment strategy as standard care for colorectal cancer patients with PC. This review summarizes the current status and possible progress in future.

© 2008 WJG. All rights reserved.

Key words: Peritoneal carcinomatosis; Cytoreductive surgery; Intra peritoneal hyperthermic chemotherapy; Gastric cancer; Colorectal cancer; Ovarian cancer; Peritoneal mesothelioma

Peer reviewer: Kazuhiro Hanazaki, MD, Professor and Chairman, Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Okohcho, Nankoku, Kochi 783-8505, Japan

al-Shammaa HAH, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008; 14(8): 1159-1166 Available from: URL: http://www.wjgnet.com/1007-9327/14/1159.asp DOI: http://dx.doi.org/10.3748/wjg.14.1159

INTRODUCTION

The loco-regional progression of gastrointestinal and gynecological cancers usually result in peritoneal carcinomatosis (PC), which is characterized by the presence of tumor nodules of various size, number and distribution on the peritoneal surface, with very poor prognosis and a median survival of less than 6 mo[1-3]. The most widely accepted therapies for such PC are systemic chemotherapy, best support care and palliative treatment, without any hope of cure. Moreover, surgery alone can only remove the bulky visible tumor nodules. For the micrometastases, invisible free cancer cells and those tumor masses not suitable for resection, surgery can not achieve any effect. Therefore, neither surgery nor chemotherapy alone can make obvious positive impact on the survival and quality of life in patients with PC. In order to tackle this difficult problem, a new treatment modality called cytoreductive surgery (CRS) plus intraoperative peritoneal hyperthermic chemotherapy (IPHC) has been developed over the past two decades, which has the advantages of surgery to reduce the visible tumor burden and regional hyperthermic chemotherapy to eradicate micrometastases and free cancer cells[4]. Over the past decade, this treatment modality has gained increasingly wide acceptance in clinical practice and in some cancer centers in Europe, America, Japan and Australia, and has been adopted as the treatment of choice for PC from gastrointestinal tract or pelvic malignancies. This paper summarizes the biological basis, the indications and contraindications, the techniques, the efficacy and safety issues and future directions of this new treatment.

INCIDENCE, MORBIDITY AND MORTALITY OF PC

PC is a direct consequence of loco-regional progression...
of gastrointestinal and gynecological cancers including gastric cancer (GC), colorectal cancer (CRC), ovarian cancer (OC), appendiceal cancer and malignant peritoneal mesothelioma.

For GC, 10%-20% of patients being explored for potentially curative resection are found to have peritoneal seeding at the time of abdominal exploration. This occurs most frequently in patients with signet ring cell type of GC as opposed to intestinal type pathology[9]. Furthermore, peritoneal recurrence develops in 60% of patients with T3 or T4 tumor after curative resection[6]. In T3 or T4 tumor, invisible micrometastases are already present in the peritoneal cavity at the time of curative resection, and peritoneal recurrence is the only site of the first recurrence in 40%-60% of patients[7-9]. Therefore, peritoneal dissemination alone usually results in death of 20%-40% of patients with GC[10].

For CRC, peritoneal seeding of cancer cells leading to PC is rather common. It is estimated that, at the time of diagnosis, the peritoneal surface is already involved in 8%-15% of CRC cases, and that initial recurrence in the peritoneum occurs in up to 50% of patients after curative surgery[11-14]. In approximately 25% of patients with recurrent CRC, the peritoneal cavity seems to be the only metastatic site of the disease, even after a detailed diagnostic workup of the liver and lungs[15].

OC is another malignancy prone to peritoneal metastasis. About 50%-75% of women with OC will develop persistent or recurrent disease with a long survival rate in only 25% patients[16,17]. In about 82% of the cases, the recurrence is within the peritoneal cavity while in 12% it occurs in the retroperitoneal lymph nodes[18-20]. For early stage OC, the median recurrence time ranged between 11 mo and 29 mo with much more involvement of the pelvis or abdomen than retroperitoneal lymph nodes[21-28]. For advanced OC, if the initial treatment achieves meaningful clinical response, the median recurrence time ranges from 18 mo to 24 mo, again with peritoneal metastasis as the most common site[16,29-34].

**MECHANISMS OF PC DEVELOPMENT**

PC is formed through a multi-step process (Figure 1): (1) detachment of cancer cells from primary tumor. The origin of PC in GC, for example, is considered to be the intraperitoneal free cancer cells, which are exfoliated from the serosal surface of the primary tumor; (2) intraperitoneal free cancer cells attach to the distant peritoneum, and invade into the subperitoneal space; (3) invasion into subperitoneal space; and (4) proliferation with vascular neogenesis[35-38].

Recent studies have revealed special anatomical basis for peritoneal metastasis. Yonemura et al[39] found special peritoneal lymphatic orifices, which are referred to as the lymphatic stomata and connect with subperitoneal lymphatic channel and milky spots. Milky spots are the minute organelles which contain lymphatic vessels, lymphocytes, and peritoneal macrophages. Milky spots distribute mainly on the greater omentum and pelvic peritoneum. Intraperitoneal free cancer cells specifically deposit in the lymphatic stomata and proliferate in the submesothelial lymphatic space. The lymphatic stomata showed special distribution on the peritoneal surface. Numerous stomata are detected on the undersurface of the diaphragm, small bowel mesentery, greater omentum, appendix epiploicae of the large bowel and the pelvic peritoneum. In contrast, there are no lymphatic stomata on the liver capsule, the surface of the spleen and the serosal surface of the small bowel and stomach. Accordingly, the serosal surface of these organs is involved only at the late phase of peritoneal dissemination.

**CURRENT TREATMENT STRATEGIES AGAINST PC**

For a long time, PC has been considered as a preterminal condition and treated with systemic chemotherapy alone with poor outcome; and the role of surgery is just palliative to relieve intestinal obstruction. But at least 1 phase III and many phase II studies have shown that the use of CRS with IPHC can improve survival for PC. Currently, such method of treatment has evolved into a novel approach for PC and might represent the standard care in selected patients (Figure 2)[38,40].

**Rationale**
Intraoperative use of chemotherapeutic agents to maximize
the efficacy of both surgery and chemotherapy has many advantages. First, surgery can separate the adhesions and remove the bulky tumor, leaving microscopic residual tumors much more susceptible to the killing effect of chemotherapeutic drugs. Second, intraperitoneal chemotherapy has distinct pharmaceutical advantages. In a recent phase I study by Morgan et al[41], 36 patients with PC of different origin were treated with intraperitoneal gemcitabine chemotherapy. It was found that the median peak peritoneal concentration was 1116 folds (range, 456-1886) higher than the peak plasma level. This could increase the local drug concentration, thus intensifying its direct antitumor effect while reducing the systemic adverse effects. Such preferential high concentration of drugs in the peritoneal cavity also occurs in many other drugs such as doxorubicin, melphalan, mitomycin C, cisplatin, gemcitabine, mitoxantrone, oxaliplatin, etoposide, irinotecan, paclitaxel, docetaxel, 5-fluorouracil, fluorouracil and carboplatin[42]. Third, heat itself has direct detrimental effect on the growth of cancer cells. Cell membrane, cytoskeletons, synthesis of macromolecules, and DNA repair mechanisms are all affected by hyperthermia[38]. Temperature over 43°C has direct cytostatic effect on human breast cancer cell line MCF-7, ovarian SKOV-3 and hepatocarcinoma HepG2 cells[43]. Fourth, the synergistic effect of hyperthermia and chemotherapy has also been well-documented. It has been shown that hyperthermia increases the cytotoxicity of some chemotherapeutic agents[43-45]. Because of these advantages, CRS plus IPHC has been increasingly used in the treatment of PC from GC[40], malignant mesothelioma[47], appendiceal cancer[48], CRC and OC[49-50].

**Indications, contraindications and patient selection**

IPHC is commonly indicated for the treatment of PC with GC, CRC, appendiceal cancer, OC, peritoneal mesothelioma, pseudomyxoma peritonei and malignant ascites, if the patients can stand CRS and IPHC.e.g those with renal and myocardial impairments; (2) there is an extra-abdominal disease; (3) parenchymal hepatic metastases; (4) bulk retroperitoneal disease; (5) the peritoneal tumor is incompletely resected or can not be significantly reduced; and (6) patients aged over 70 years[38].

A clear preoperative staging of PC is necessary for such treatment. Preoperative abdominopelvic CT, MRI, positron emission tomography (PET) or PET/CT, or laparoscopy are adequate procedures[50].

**Techniques**

Complete CRS is vital in improving the survival of patients with PC, although in some patients with limited PC, partial removal of peritoneum is enough to eliminate macroscopic disease[61]. The goal of complete CRS is to remove all macroscopic peritoneal dissemination. Peritonectomy consists of two big surgical components (parietal and visceral peritonectomy). A midline incision extending from xiphoid process to pubis is sometimes necessary, complete parietal peritonectomy can be achieved by stripping off the parietal peritoneum at the abdominal incision, then ascending colon, spleen, pancreatic tail, and descending sigmoid colon are mobilized, and all peritoneum lining the lower abdominal wall and pelvis is removed. Visceral peritonectomy includes subtotal colectomy, omentectomy, partial gastrectomy, and resection of mesentery to the extent that they are involved[60].

It is mandatory to examine the greater omentum, undersurface of diaphragm and Douglas pouch as free cancer cells can lodge there due to presence of lymphatic stomata[60]. Micrometastasis on the preserved peritoneum can be managed by intraperitoneal chemotherapy, so complete cytoreduction includes the removal of peritoneum with gross nodules[38,61,62].

After finishing CRS, IPHC is initiated. It has been shown that hyperthermia augments the penetration of anticancer drugs[63], in addition to its synergistic cytotoxicity on cancer cells when combined with some chemotherapeutic drugs such as mitomycin C (MMC) and cisplatin[64]. It is performed either with open or closed techniques, with more advantages of the former due to uniform distribution of the chemotherapeutic agents within peritoneal cavity[60]. In either technique, large volume (5 L-10 L) of saline heated at 42°C-43°C is introduced into the peritoneal cavity and circulated at a high flow rate of about 10 L/min[60]. The total dose of MMC and CDPP should be 30 mg and 300 mg, respectively with an optimal duration of 60-90 min[60].

**ASSESSMENT OF COMPLETENESS OF CRS**

There is agreement among many treatment centers that the extent of disease prior to CRS and the completeness of cytoreduction (CCR) score are the principal prognostic indicators for survival[14,38,66-85]. In CCR, the extent of residual disease after CRS is classified into 4 categories: CCR-0 indicating no visible residual tumor; CCR-1, residual tumor ≤ 2.5 mm in diameter; CCR-2, residual tumor between 2.5 mm and 2.5 cm; and CCR-3, residual tumor > 2.5 cm or confluence of disease present at any site[66]. But those with more diffuse disease (more than 2 quadrants) become worse no matter how good a cytoreduction procedure is. The understanding of a complete cytoreduction may vary according to the disease process, for example, in colorectal PC, complete cytoreduction needs a CCR-0 score[14,66-85] while in pseudomyxoma peritonei, a complete cytoreduction may involve both CCR-0 and CCR-1[39,87].
**Table 1** The survival rates of CRS plus IPHC in patients with PC of different malignancies

| Authors            | Pts | Year | Study type | Tumor type | Drugs, temperature & duration | Median follow-up time | 1 yr | 2 yr | 3 yr | 4 yr | 5 yr |
|--------------------|-----|------|------------|------------|-------------------------------|------------------------|------|------|------|------|------|
| Pilati et al.      | 34  | 2003 | Phase II   | Colon ca   | MMC 26.2 mg (20.1-31.6 mg) CDDP 193.7 mg (170-241.1 mg), 41.5°C (41.2°C-42°C), 90 min | 14.5 mo (6-34 mo)     | 68   | 31   | -    | -    | -    |
| Glehen et al.      | 56  | 2003 | Phase II   | CRC, OC, GC, peritoneal Mesothelioma, Pseudomyxoma peritonei, and others | MMC 0.7 mg/kg (max dose 60 mg), CDDP 1 mg/kg (max dose 80 mg), 46°C-48°C, 90 min | 544.4 d (133-1680 d) | R0: 79.0; R2: 44.7 |
| Verwaal et al.     | 54  | 2003 | Phase III  | CRC        | MMC 70 mg, 41°C-42°C, 90 min | 21.6 mo                | 67   | 44   | -    | -    | -    |
| Winkamp et al.     | 29  | 2001 | Phase I / II | CRC   | MMC 35 mg/m², 40°C-41°C, 90 min | 38 mo (26-52 mo)        | 82   | 45   | 23   | -    | -    |
| Shen et al.        | 77  | 2004 | Phase II   | CRC        | MMC 40 mg, 40.5°C, 120 min | 15 m                   | 56   | 25   | 17   | -    | -    |
| Elias et al.       | 24  | 2004 | Phase II   | CRC        | LOHP 460 mg/m² in 2 L/m², 4°C-30°C, 30 min | 27.4 mo                | 83   | 74   | 65   | -    | -    |
| Yonemura et al.    | 107 | 2005 | -          | GC         | MMC 30 mg, CDDP 300 mg, etoposide 150 mg, 42°C-43°C | 46 mo                   | -    | -    | -    | 6.7 all pts; 27 R0 pts |
| Yonemura et al.    | 48  | 2001 | Randomized study | T2-T4 GC | MMC 30 mg, CDDP 300 mg, 42°C-43°C, 60 min | 5.5 yr (2.4-10.8 yr) | -    | -    | -    | 61   | -    |
| Elias et al.       | 30  | 2006 | Phase II   | CRC        | LOHP 460 mg/m² in 2 L/m² of iso-osmotic 5% dextrose, 43°C, 30 min | 55 mo (24-80 mo)       | 97   | 73   | 53   | 49   | -    |
| Yan et al.         | 30  | 2006 | -          | CRC        | -                         | 12 mo                  | 72   | 64   | -    | -    | -    |
| Glehen et al.      | 53  | 2004 | Phase II   | CRC        | MMC 40-60 mg, 46°C-48°C, 90 min | 60 mo                  | 55   | 32   | -    | -    | 11   |
| Helm et al.        | 18  | 2007 | Retrospective review | Recurrent OC | CDDP 100 mg/m² or MMC 30-40 mg, 41°C-43°C, 90 min | 16.2 mo (6-33 mo)      | -    | -    | -    | -    | -    |
| Deraco et al.      | 33  | 2004 | Phase II   | Pseudomyxoma peritonei | CDDP 25 mg/m² per L plus MMC 3.3 mg/m² per L, 60 min, 42.5°C | 28.6 mo (0.4-72 mo) | -    | -    | -    | 97   | -    |
| Cavaliere et al.   | 69  | 2003 | Phase II   | CRC        | MMC                         | -                      | -    | -    | 27   | -    | -    |
| Giale et al.       | 506 | 2004 | Phase II   | CRC        | MMC/LOHP, 40°C-43°C, 30-90 min | 53 mo                  | 72   | 39   | -    | 19   | -    |
| Verwaal et al.     | 117 | 2005 | Phase II   | CRC        | MMC 35 mg/m², 40°C-41°C, 90 min | 46 mo                  | 75   | 28   | -    | -    | -    |
| Sugarbaker et al.  | 70  | 2006 | Phase II   | CRC        | MMC                         | 47 mo                  | 88   | 44   | -    | 32   | -    |
| Helm et al.        | 5   | 2007 | Retrospective review | Recurrent endometrial ca | CDDP 100 mg/m², 41°C-43°C, 90 min | 36 mo                  | 80   | 80   | 80   | -    | -    |
| Zanon et al.       | 25  | 2006 | Phase II   | CRC        | MMC 15 mg/m², 42°C, 60 min | 36 mo                  | 64   | 40   | -    | -    | -    |
| Piso et al.        | 19  | 2004 | -          | OC         | CDDP 75 mg/m², or mitoxantrone 15 mg/m², 41.5°C, 90 min | -                      | -    | -    | -    | 15   | -    |
| Roviello et al.    | 59  | 2006 | -          | OC, CRC, GC, Pseudomyxoma, Peritoneal Mesothelioma | MMC 25 mg/m², CDDP 100 mg/m². (LOHP 460 mg/m² in 4 pts with colorectal PC), 41°C-43°C, 60 min | 25 ± 21 mo | -    | -    | -    | 50.8 |

GC: Gastric cancer; CRC: Colorectal cancer; OC: Ovarian cancer; MMC: Mitomycin C; CDDP: Cisplatin; LOHP: Oxaliplatin.

**Efficacy and Benefit of CRS Plus IPHC**

It is now clear that CRS plus IPHC improves both the quality of life especially in patients with malignant ascites and the survival. The results of the most significant studies about the survival rates are summarized in Table 1, which supports the use of this new modality as standard care.

**Adverse Events of IPHC**

IPHC is associated with a high morbidity rate ranging from 27% to 56%. The adverse events can be classified into CRS-related and chemotherapy-related morbidity. Surgery-related adverse events are abscess, intestinal perforation, fistula, prolonged ileus, bile leakage, pancreatitis, pneumonia, deep vein thrombosis, pulmonary emboli, cardiac insufficiency and cerebral infarcts.
Multivariate analysis demonstrated that adverse events are related to the stage of PC, the operation duration, the number of Anastomoses, and blood loss[10,8]. Main chemotherapy-related side effects are bone marrow suppression and renal insufficiency mostly with use of cisplatin[11]. The mortality rate for IPHC ranges between 0% and 11%, and the most common causes of death are bowel perforation, bone marrow suppression, respiratory failure, methicillin resistant staphylococcus aureus infection, and pulmonary embolism[10].

In spite of the above morbidities, such modality remains the suitable one if not the best at present because the patients with PC might get worse without it as systemic chemotherapy or surgery alone is associated with much poorer outcome. With careful and accurate selection of patients, excluding those who are unfit, it is possible to reduce the morbidities of CRS + IPHC and yield a significantly favorable impact on improving survival of the patients.

FUTURE DIRECTIONS

Recently a panel of 55 experts in PC has reached the consensus, which stated that systemic treatment alone may be no longer appropriate for patients with limited PC from a primary or recurrent colon cancer. CRS plus IPHC as a new treatment strategy have clear advantage in this setting[89]. Such procedure has been approved by the surgical oncology experts on PC from North America, France, Italy, Germany, Holland, Spain and Australia. The consensus also indicated that patients who have isolated PC and are likely to receive a complete cytoreduction, as determined by preoperative CT scans, should undergo CRS; and if complete cytoreduction is achieved, intraperitoneal hyperthermic MMC should be given (at 15-35 mg/m², 39°C-42°C, for 60-120 min, either by closed or open instillation), followed by best adjuvant systemic chemotherapy[10].

Several issues have been discussed about the future of this treatment strategy, one of which is how to make such therapy standardized and available to large numbers of patients. The operative procedures required for aggressive cytoreduction are lengthy, challenging and morbid and use a great deal of hospital, blood bank, and operational theater resources[10]. Even though this treatment strategy has been confirmed to be effective in some centers, there is only one randomized clinical trial to definitely establish its efficacy in terms of improving the survival and the quality of life of patients with colorectal PC[90,63]. Currently, a large scale prospective multi-center phase II study using CRS and IPHC with MMC followed by modern adjuvant systemic chemotherapy for patients with isolated colorectal PC is in progress. This study involves 66 peritoneal surface malignancy surgeons from 46 institutions in 16 countries. Once completed, this study will provide better evidence as to the efficacy of this treatment modality[90].

It is clear that CRS plus IPHC is not indicated for all patients with PC, and the results achieved by international experts in this field may not be replicated in routine clinical practice. Patients with good performance status, low volume of peritoneal disease, and absence of extra-abdominal metastases are more likely to benefit from the combined treatment. This means early diagnosis, early referral to specialist peritonectomy centers for staging, and prompt intervention are keys to successful management. Only by collaborative efforts from medical oncologists, surgical oncologists, and peritoneal surface malignancy treatment centers can such result be achieved[89].

REFERENCES

1 Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001; 8: 632-637
2 Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550
3 Sagdeh B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaunard E, Brachet A, Cailliot JL, Faure JL, Porcheron J, Poix JL, Francois V, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCATE 1 multicentric prospective study. Cancer 2000; 88: 358-363
4 Mori T, Fujiwara Y, Sugita Y, Azama T, Ishii T, Taniguchi K, Yamazaki K, Takiguchi S, Yasuda T, Yano M, Monden M. Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric cancer. Ann Surg Oncol 2004; 11: 14-20
5 Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000; 58: 96-107
6 Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-262
7 Iitsuuka Y, Kaneshima S, Tanida O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 1979; 44: 1476-1480
8 Koga S, Kaibara N, Iitsuuka Y, Kudo H, Kimura A, Hiraoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984; 108: 236-238
9 Yonemura Y. Hyperthermo-chemotherapy for the treatment of peritoneal dissemination. In: Yonemura Y, editor. Contemporary approached toward cure of gastric cancer. Kanazawa: Maeda Shoten, 1996: 105-116
10 Yonemura Y, Bando E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am 2003; 12: 635-648
11 Portilla AG, Cendonua I, Lopez de Tejada I, Olibariba I, Martinez de Lecea C, Magrach L, Gil A, Echevarria J, Valdovinos M, Larrabide I. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update. Rev Esp Enferm Dig 2005; 97: 716-737
12 Sugarbaker PH, Cunliffe WJ, Belliveau J, de Brujin EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1999; 16: 85-97
13 Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019
14 Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71
15 Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal www.wjgnet.com
carcinomatosis of colorectal origin: incidence and current treatment strategies. 

16 Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 2005; 55: 153-166

17 Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005; 15 Suppl 1: 3-11

18 Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep 2001; 3: 11-18

19 Gadducci A, Sartori E, Muggino T, Zola P, Landoni F, Fanucchi A, Clesi A, Ferrero AM, Cosio S, Cristofani R. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 1998; 68: 150-155

20 Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetes AA, Massuger LF. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007; 120: 2710-2714

21 Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112

22 Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027

23 Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, Trope CG. Randomized trial comparing cisplatin to no further treatment or wholeabdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741-749

24 Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Stettner H, Winter R. Lymphadenectomy in stage I ovarian cancer. J Clin Oncol 1994; 12: 594-602

25 Petru E, Lahoussen M, Tamussino K, Pickel H, Stranzl H, Stettner H, Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 658-662

26 Malmstrom H, Simonsen I, Westberg R. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 1994; 52: 20-25

27 Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, Chiari S, Favalli G, Mangili G, Presti M. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chormic phosphate (32P). J Gynaecol Oncol. Gruppo Intergionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6: 887-893

28 Gadducci A, Sartori E, Muggino T, Zola P, Landoni F, Fanucchi A, Stegger C, Alessi C, Buttitta F, Bergamin TE. Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study. Int J Gynecol Cancer 1997; 7: 445-450

29 Mano MS, Awada A, Minisini A, Atalay G, Lago LD, Cardoso F, Piccart M. Remaining controversies in the upfront management of advanced ovarian cancer. Int J Gynecol Cancer 2004; 14: 707-720

30 Podratz KC, Malkasian GD Jr, Wiegand HS, Cha SS, Lee RA, Stanhope CR, Williams TJ. Recurrent disease after negative second-look laparotomy: in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274-282

31 Rubin SC, Hoskins WJ, Hakes TB, Markman M, Caim JM, Lewis J Jr. Recurrence after negative second-look laparotomy for ovarian cancer: an analysis of risk factors. Am J Obstet Gynecol 1988; 159: 1094-1098

32 Bar-Am A, Kovner F, Lessing JB, Inbar M, Chaitichik S, Azem F, Brenner SH, Peyser MR. A second thought on second look laparotomy. Acta Obstet Gynecol Scand 1993; 72: 386-390

33 Thigpen JT. Current controversies in ovarian cancer: maintenance chemotherapy as standard care. In: Perry MC, editor. American Society of Clinical Oncology. 2004 Educational Book, 40th Annual Meeting; June 5-8, New Orleans, LA, Alexandria, VA: USA Greves 2004: 281-284

34 Gadducci A, Cosio S, Zola P, Landoni F, Muggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 2007; 17: 21-31

35 Yonemura Y, Endou Y, Fujisada S, Bandou E, Taniguchi K, Miwa K, Sugiyama K, Sasaki T. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000; 3: 63-70

36 Liotta LA. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986; 46: 1-7

37 Yonemura Y, Bandou E, Kawamura T, Endou Y, Sasaki T. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006; 32: 602-606

38 Stewart JH 4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12: 765-777

39 Yan TD, Sim J, Morris DL. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2007; 14: 1807-1817

40 de Roover A, Detroz B, Detory O, Coimbra C, Polus M, Belaiche J, Meurisse M, Honore P. Adjuvant intraperitoneal chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience. Acta Chir Belg 2006; 106: 297-301

41 Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tsetef M, Lin P, Paz B, Koczyswas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2007; 13: 1232-1237

42 Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10: 112-122

43 Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgopoulos V, Tsiftsis DD, Theodoropoulos PA. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 2007; 14: 1220-1228

44 Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003; 12: 689-701

45 Mohamed F, Marchetti P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10: 463-468

46 Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M, Okubo H. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79: 884-891

47 Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Ann Surg 2001; 6: 999-1005

48 Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727-731

49 Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Vezon DJ, Alexander HR. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83: 1251-1261
50 Loggie BW, Sterchi JM, Rogers AT, Lentz S, Holmesley H, Charles D, Sundberg D. Intrapertioneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Cancer Treat Rep 1994; 78:7-18

51 Cavaliere F, Perri P, Di Filippo P, Giannarelli D, Botti C, Cosimelli M, Tedesco M, Principi F, Laurenni L, Cavaliere R. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000; 74: 41-44

52 van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huink WW, Beijnen JH. Extensive cytoreductive surgery combined with intraoperatively intraperitoneal perfusion with cisplatin under hypothermic conditions (OVHPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26: 663-668

53 Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Rasagliesi F, Kusamura S, Vaglini M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001; 87: 120-126

54 Panteix G, Beaujard A, Garbit F, Chauduron-Faye C, Guillaumont M, Gilly F, Balassat P, Bressolle F. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22: 1329-1336

55 Helm CW, Randall-Whits L, Martin RS 3rd, Metzinger DS, Gordiner ME, Parker LP, Edwards RP. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105: 90-96

56 Zanon C, Clara R, Chiappino I, Bertolini M, Cornaglia S, Simone P, Bruno F, De Rui L, Airoldi M, Pedani F. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004; 28: 1040-1045

57 Reichman TW, Craciun B, Sama J, Bryan M, Harrison J, Pliner L, Harrison LE. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 2005; 90: 51-56; discussion 56-58

58 Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004; 14: 35-41

59 Steller MA, Cancer MJ, Trimble EL, Bartlet DL, Zuhowski EG, Alexander HR, Dedrick RL. A pilot phase I trial of continuous intraperitoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43: 106-114

60 Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37: 979-984

61 Yonemura Y, Kawamura T, Nojima N, Bandou E, Keizou T, Fujita H, Mihara Y, Fujimura T, Fushida S, Ajiroka H, Miwa K. Prognostic factors of 51 peritoneal carcinomatosis of colorectal origin: a phase II clinical study. Tumori 2001; 87: 120-126

62 Yonemura Y, Kawamura T, Nojima N, Bandou E, Keizou T, Fujita H, Mihara Y, Fujimura T, Fushida S, Ajiroka H, Miwa K. Prognostic factors of 51 peritoneal carcinomatosis of colorectal origin: a phase II clinical study. Tumori 2001; 87: 120-126

63 Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69: 235-241

64 Yonemura Y. Hyperthermo-chemotherapy for treatment of peritoneal dissemination. In: Yonemura Y, editor. Peritoneal dissemination. Kanazawa: Maeda Shoten 1998: 1-46

65 Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69: 235-241

66 Giehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bender JM, Porcheron J, Gomez-Porilla A, Shen P, Deraco M, Rat F. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22: 3284-3292

67 Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743

68 Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy, Ann Surg 1995; 221: 124-132

69 Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20: 585-591; discussion 592

70 Pestelie SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of comitant vs. delayed management. Dis Colon Rectum 2000; 43: 1341-1346; discussion 1347-1348

71 Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hemogenous metastasis from colorectal cancer. Eur J Surg Oncol 2004; 30: 391-399

72 Gomes da Silva R, Sugarbaker P. Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am J Surg 2006; 203: 878-886

73 Hadi R, Saunders V, Utikina O, Cingan P, Kam P, Links M, Morris DL. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006; 76: 156-161

74 Shehata M, Chu F, Saunders V, Kam PC, Links M, Morris DL. Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy. ANZ J Surg 2006; 76: 467-471

75 Yan TD, Chu F, Links M, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol 2006; 32: 1119-1124

76 Kecmanovic DM, Pavlov MJ, Ceranic MS, Sepetkovski AV, Kovacevic PA, Stamenkovic AB. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31: 147-152

77 Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004; 91: 739-746

78 Giehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 747-754

79 Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23: 23-29

80 Gomes da Silva R, Cabanas J, Sugarbaker PH. Limited survival in the treatment of carcinomatosis from rectal cancer. Dis Colon Rectum 2005; 48: 2258-2263

81 Giehen O, Mittieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21: 799-806
